Brief: India's Panacea Biotec Completes Phase I/II Study Of Dengue Vaccine Candidate

Panacea Biotec

24/09/2020 13:31

Sept 24 (Reuters) - Panacea Biotec Ltd  PNCA.NS :
    * SUCCESSFUL COMPLETION OF PHASE I/II STUDY OF ITS NOVEL,
TETRAVALENT RECOMBINANT CHIMERIC DENGUE CANDIDATE VACCINE,
DENGIALL
    * DENGIAIL FOUND TO BE SAFE, WELL-TOLERATED WITH NO SERIOUS
ADVERSE EFFECTS
    * HAS APPROACHED REGULATORS TO SEEK ACCELERATED REVIEW OF
DATA TO
BRING DENGIAIL TO MARKET QUICKLY

Source text for Eikon:  ID:nBSEQ8svr 
Further company coverage:  PNCA.NS 

 ((bangalore.newsroom@thomsonreuters.com;))